🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Orbimed Advisors reduced stake in 89bio

Published 09/23/2020, 05:28 PM
Updated 09/23/2020, 05:30 PM
© Reuters.  Orbimed Advisors reduced stake in 89bio
BIIB
-
ALXN
-
NBIX
-
CRNX
-
ETNB
-

On the 21st of September, Orbimed Advisors sold 275 thousand 89bio, Inc. (NASDAQ:ETNB) shares for $7.7 million at an average price of $28.00 per share. Shares of 89bio, Inc. are down -2.64% since the transaction.

Orbimed Advisors's holding in 89bio, Inc. decreased to about 1.9 million shares with the transaction.

Orbimed Advisors first bought 89bio, Inc. stock in the fourth quarter of 2019. Orbimed Advisors also owns Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Biogen Inc (NASDAQ:BIIB), Neurocrine Biosciences Inc (NASDAQ:NBIX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). 89bio, Inc. is its number twelve position by number of shares and market value among pharmaceuticals stocks.

In contrast, Millennium Management and Point72 Asset Management established new holdings in 89bio, Inc.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.